Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0250/2023

Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0282/2023

List of industry subject matter experts and list of planned calls for industry subject matter experts

Herbal medicinal product: Ginseng radixArray, F: Assessment finalised

Herbal medicinal product: Pelargonii radixArray,Array, F: Assessment finalised

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 6, Status: Authorised

Public webinar on pack size submissions: from XEVMPD to product management service (PMS), Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 10:00 (CEST) to 11 July 2024, 11:30 (CEST)

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 15, Status: Authorised